Dupilumab improves in diverse aspects of eosinophilic esophagitis

Weekly dupilumab demonstrated significant and clinically meaningful improvements in histologic, symptomatic, endoscopic, and molecular aspects of eosinophilic esophagitis (EoE).

Weekly dupilumab demonstrated significant and clinically meaningful improvements in histologic, symptomatic, endoscopic, and molecular aspects of eosinophilic esophagitis (EoE). In addition, dupilumab was well tolerated. That was found in part A of an ongoing 3-part, randomized, placebo-controlled, phase 3 study1.

EoE is a chronic type 2 inflammatory disease of the esophagus that can substantially impair the quality of life. Only a few treatment options are currently available and the response to the current therapy is generally suboptimal.

Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 and IL-13. These cytokines are key drivers of type 2 inflammation in EoE. In a previous phase 2 proof-of-concept study, dupilumab significantly improved histological and clinical outcomes of EoE with an acceptable safety profile. In the current, ongoing, phase 3 trial, the efficacy and safety of weekly dupilumab 300 mg are compared with placebo in 81 adult and adolescent patients with EoE with a treatment duration of 24 weeks.

The first primary endpoint was the proportion of patients achieving a peak esophageal intraepithelial eosinophil count of ≤6 eosinophils per high-power field. At week 24, a significantly higher proportion of patients treated with dupilumab versus placebo achieved:

Furthermore, dupilumab-treated versus placebo-treated patients had a significantly greater percent change from baseline in:

Dupilumab was generally well tolerated with an acceptable safety profile. The most common treatment-emergent adverse events for dupilumab versus placebo were injection-site reactions (16.7% vs 10.3%) and nasopharyngitis (11.9% vs 10.3%).

Source:
1. Dellon ES. Dupilumab efficacy and safety in adult and adolescent patients with eosinophilic esophagitis: results from part A of a randomized, placebo-controlled three-part, phase 3 study. UEG Week E-congress 2020, abstract LB22.

Esanum is an online network for approved doctors

Esanum is the medical platform on the Internet. Here, doctors have the opportunity to get in touch with a multitude of colleagues and to share interdisciplinary experiences. Discussions include both cases and observations from practice, as well as news and developments from everyday medical practice.

Esanum ist ein Online-Netzwerk für approbierte Ärzte

Esanum ist die Ärzteplattform im Internet. Hier haben Ärzte die Möglichkeit, mit einer Vielzahl von Kollegen in Kontakt zu treten und interdisziplinär Erfahrungen auszutauschen. Diskussionen umfassen sowohl Fälle und Beobachtungen aus der Praxis, als auch Neuigkeiten und Entwicklungen aus dem medizinischen Alltag.

Esanum est un réseau en ligne pour les médecins agréés

Esanum est un réseau social pour les médecins. Rejoignez la communauté et partagez votre expérience avec vos confrères. Actualités santé, comptes-rendus d'études scientifiques et congrès médicaux : retrouvez toute l'actualité de votre spécialité médicale sur esanum.